⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CORT News
Corcept Therapeutics Inc.
Alger Russell Innovation Index Updates for Fourth Quarter 2025
prnewswire.com
CCC
DOX
DUOL
FFIV
GDDY
GNTX
ZBRA
CORT
EA
GILD
JNJ
QRVO
UTHR
VRTX
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
businesswire.com
CORT
Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
businesswire.com
CORT
Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025
businesswire.com
CORT
FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
businesswire.com
CORT